Multifunctional Nanoparticles Overcome Drug Resistance in Cancer

Strategic Insights -

Researchers in the United States have made significant advancements in cancer gene therapy by developing multifunctional nanoparticles that can deliver small interfering RNA and doxorubicin, overcoming drug resistance in cancer. This breakthrough study, published in the Journal of Biological Chemistry, showcases two nanoparticle formulations, LPD and LPD-II, designed to co-deliver doxorubicin and therapeutic siRNA to multiple drug resistance tumors.

Key Takeaways:

  • The researchers developed two nanoparticle formulations, LPD and LPD-II, for systemic co-delivery of doxorubicin and siRNA to MDR tumors.
  • The LPD nanoparticles were formulated with a guanidinium-containing cationic lipid, which induced reactive oxygen species and increased doxorubicin uptake.
  • The researchers co-delivered vascular endothelial growth factor siRNA and doxorubicin to block angiogenesis and increase drug penetration.
  • LPD-II showed higher entrapment efficiency of doxorubicin and lower P-glycoprotein-mediated drug efflux than LPD.
  • The study demonstrated the first evidence of c-Myc siRNA delivered by LPD-II down-regulating MDR expression and increasing doxorubicin uptake in vivo.
  • In the study, three daily intravenous injections of therapeutic siRNA and doxorubicin co-formulated in either LPD or LPD-II nanoparticles showed a significant improvement in tumor growth inhibition.
  • Chen and colleagues compared the activity and toxicity of LPD-and LPD-II-mediated therapy.
  • This study highlights a potential clinical use for multifunctional nanoparticles with an effective delivery property and a function to overcome drug resistance in cancer.

Statistics:

  • The study used three daily intravenous injections of therapeutic siRNA and doxorubicin (1.2 mg/kg) co-formulated in either LPD or LPD-II nanoparticles.
  • The wild-type (MDR+/-) mice were dosed with LPD and LPD-II nanoparticles at 1.2 mg/kg for 21 days.
  • LPD-II showed a 2.5-fold increase in doxorubicin entrapment efficiency compared to LPD.

Sources:

  • Chen et al. (2010). Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. Journal of Biological Chemistry, 285(29), 22639-22650.
  • Cancer Gene Therapy Journal.
  • University of North Carolina, Department of Molecular Pharmaceutics.